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Abstract
Background: Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular and renal events. Statins are
widely prescribed to reduce cardiovascular risk and to slow down progression of kidney disease. But statins may also
generate tubular MAU. The current observational study evaluated the impact of statin use on the interpretation of MAU as a
predictor or marker of cardiovascular or renal disease.
Methodology/Principal Findings: We used cross-sectional data of ERICABEL, a cohort with 1,076 hypertensive patients.
MAU was defined as albuminuria $20 mg/l. A propensity score was created to correct for ‘‘bias by indication’’ to receive a
statin. As expected, subjects using statins vs. no statins had more cardiovascular risk factors, pointing to bias by indication.
Statin users were more likely to have MAU (OR: 2.01, 95%CI: 1.34–3.01). The association between statin use and MAU
remained significant after adjusting for the propensity to receive a statin based on cardiovascular risk factors (OR: 1.82,
95%CI: 1.14–2.91). Next to statin use, only diabetes (OR: 1.92, 95%CI: 1.00–3.66) and smoking (OR: 1.49, 95%CI: 0.99–2.26)
were associated with MAU.
Conclusions: Use of statins is independently associated with MAU, even after adjusting for bias by indication to receive a
statin. In the hypothesis that this MAU is of tubular origin, statin use can result in incorrect labeling of subjects as having a
predictor or marker of cardiovascular or renal risk. In addition, statin use affected the association of established
cardiovascular risk factors with MAU, blurring the interpretation of multivariable analyses.
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Introduction
Microalbuminuria (MAU) is considered as a predictor or
marker of cardiovascular morbidity and mortality, particularly in
patients with other risk factors [1–4], and as a surrogate for early
kidney damage especially in subjects with diabetes and hyperten-
sion [5,6]. Statins are frequently prescribed in patients with
hypertension, diabetes and metabolic syndrome, to reduce
cardiovascular morbidity and mortality [7]. Statins can reduce
existent proteinuria [8–10] through a positive impact on
endothelial dysfunction. In contrast, there is in vitro [11,12] and
in vivo [13–16] evidence that statins are associated with de novo
albuminuria and proteinuria. It is of importance to establish the
association between statin use and MAU to correctly interpret
presence of MAU as a predictor or marker of cardiovascular or
renal disease in observational trials with a mixed population of
subjects taking and not taking a statin. If statin use is associated
with MAU, there is a risk of incorrect labeling of subjects as having
a predictor or marker of cardiovascular or renal risk. The current
study evaluated the association between statin use and MAU, and
used a propensity score analysis to adjust for bias by indication.
For this goal, we used the baseline data of the early renal
impairment and cardiovascular assessment in Belgium (ERICA-
BEL) trial, a prospective cohort of hypertensive patients followed
by primary care physicians created to evaluate the impact of
metabolic syndrome on cardiovascular and renal endpoints.
Methods
Objectives
The primary aim of the ERICABEL study was to determine the
effect of metabolic risk factors on the evolution of renal function
and cardiovascular outcome over 5 years, in patients aged between
40 and 70 years with diagnosed hypertension, and followed by
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their primary care physician. The current analysis was designed to
evaluate 1u the association between statin treatment and MAU
and 2u the impact of statin treatment on the interpretation of the
association between individual cardiovascular risk factors and
MAU in epidemiological studies.
Participants
We used the baseline data of the ERICABEL cohort, a non-
interventional epidemiological study with a follow up of 5 years
that included 1,076 Caucasian patients with hypertension, defined
as systolic blood pressure $140 mmHg and/or intake of at least
one antihypertensive drug, recruited by 96 general practitioners,
between 2006 and 2007, in Belgium. Of the 1076 patients
included in this cross-sectional study, 420 patients had a missing
value for at least one of the variables under investigation (see
appendix table S1 for detailed list). Multiple imputation techniques
were used to account for the missing data, using 20 imputations
[17]. All characteristics and outcome (MAU) were simultaneously
used in the imputation model. The imputation was done using the
R function aregImpute from the Hmisc package [18].
Description of procedures
Each participating primary care physician was asked to include
10 consecutive hypertensive patients aged between 40–70 years, in
a 1:1 sex ratio. The eligible persons were evaluated at baseline and
if eligible, sociodemographic information (age, sex, race, and
education level), personal and family medical history, smoking
status and medication use were collected prospectively in an online
database. Body weight was recorded to the nearest 0.1 Kg and
height was measured to the nearest centimeter. Body mass index
(BMI) was calculated as body weight in Kg divided by height2 (kg/
m2). Blood pressure was measured according to the WHO criteria
with a calibrated Omron HEM-907 device (average of 2
measurements, sitting, with 5 minutes in between). All these
measurements were done by the primary care physician. After
exclusion of a urinary infection or hematuria (negative ComburH
test), MAU was screened by a MicralH dipstick test. MAU was
considered present if measured albuminuria was $20 mg/l on a
morning midstream urine sample. Blood sampling was performed
by the general practitioner in fasting patients.
Definitions
The metabolic syndrome was defined as three or more of the
following criteria, according to the National Cholesterol Education
Program Third Adult Treatment Panel guidelines ATP III criteria
[19]: elevated blood pressure .130/85 mmHg and/or antihyper-
tensive medication (by definition 100% in this cohort), (2) high
plasma triglycerides (.1.7 mmol/l), low HDL cholesterol
(,1.0 mmol/l in men and ,1.3 mmol/l in women), (4)
abdominal adiposity (waist circumference .102/88 cm men/
women) and/or impaired glucose tolerance (IGT) (fasting plasma
glucose .6.1 mmol/l and/or known diabetes).
Ethics
The study was approved by an independent ethics committee
review board, protocol number: ML 19208. A written informed
consent was obtained from all participants.
Statistical methods
All analyses have been performed using SAS software (SAS
software, version 9.2 of the SAS System for Windows. Copyright
 2002 SAS Institute Inc.) or R Version 2.12.0 (R Foundation for
Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0,
2009) [20]. MAU was considered as a dichotomic variable.
Continuous variables were described by their mean, standard
deviation, median and interquartile range. Categorical variables
were summarised by frequencies and percentages.
A propensity score for statin use was created to correct for ‘‘bias
by indication’’. Propensity score analysis is a well established
method to adjust for confounding by indication in observational
trials [21,22]. Primarily, for the statistical analyses, 20 imputed
samples were created. In a second step, within each of the 20
samples separately, a propensity model was constructed and the
resulting propensity score was calculated for each of these patients.
The propensity model included the following variables that were
deemed to be possibly related to statin use: age, gender, BMI,
waist circumference, SBP, previous CV event, CRP, fasting
glucose, diabetes, serum uric acid, HDL and LDL cholesterol,
triglycerides, use of angiotensin converting enzyme inhibitor/
angiotensin receptor blocker (ACE-I/ARB) and smoking. Contin-
uous variables in the model were included using restricted cubic
splines: each continuous variable was included in the model using
3 dummy variables, called var1, var2 and var3. For the first 5
imputed samples, a histogram of the propensity scores was
presented by statin use (see appendix table S2). In addition, in
order to check the ability of the propensity scores to balance the
two statin groups for baseline characteristics, tables were presented
for the first 5 imputed samples, comparing the baseline
characteristics between the groups (see appendix table S3). In this
way, patients with the same ‘‘likelihood’’ or ‘‘propensity’’ to
receive a statin (i.e. in this setting mainly with comparable
cardiovascular risk factors), but in one case taking and in the other
case not taking a statin, were compared for presence of MAU.
For comparison of continuous variables, ANOVA was used,
adjusted for propensity scores, whereas for binary variables,
logistic regression analyses, also adjusted for propensity scores,
were employed. Logistic regression analyses were used to assess the
association between statin use and MAU using the ‘‘GENMOD’’
procedure in SAS. The associations were assessed in each of the 20
imputation samples separately and the results were combined
using the SAS procedure ‘‘MIANALYZE’’. The following logistic
regression models were used: 1u: Univariable model only including
statin use; 2u a model including statin use and propensity scores
(using a restricted cubic spline); 3u a model including statin use,
propensity scores and all relevant variables mentioned above.
Since the linearity assumption was deemed appropriate for all
continuous variables in the model (p.0.1 for the assessment of
linearity in the full model), the final model only included linear
terms for all variables.
Results
The baseline characteristics of the population are provided in
tables 1 and 2. There was an equal distribution in gender (51.3%
males) in the overall cohort. There was a high prevalence of
metabolic syndrome (44.5%), diabetes (19.8%), current smokers
(36.5%) and MAU (16.4%) in the overall cohort. ACE-I and/or
ARB were the most commonly prescribed antihypertensive agents
(55.9%). History of a cardiovascular event was recorded in 11.3%
of the patients. Mean age of the cohort was 57.567.5 years. One
third (30.8%) of the patients used a statin.
In univariable analysis, statin users were more likely to be male
(p,0.001), had a higher frequency of metabolic syndrome
(p,0.001), diabetes type 2 (p,0.001), MAU (p,0.001), ACE-i/
ARB treatment (p,0.001), and previous cardiovascular events
(p,0.001), were older (p,0.001), had larger BMI (p,0.001),
lower diastolic blood pressure (p = 0.02), higher fasting glucose
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Table 1. Baseline characteristics (categorical variables).
parameter No statins (N=724) Statins (N=332)
Statin use unknown
(N=20) Total (N=1076) P* P1
Female 384/724 (53%) 132/332 (39.8%) 7/19 (36.8%) 523/1075 (48.7%) ,.001 ,.001
MS 239/624 (38.3%) 172/299 (57.5%) 2/4 (50.0%) 413/927 (44.6%) ,.001 ,.001
Diabetes 98/700 (14.0%) 104/327 (31.8%) 2/5 (40.0%) 204/828 (19.8%) ,.001 ,.001
Smoker 249/698 (35.7%) 123/325 (37.9%) 3/5 (60.0%) 375/653 (36.5%) 0.438 0.501
MAU 68/529 (12.9%) 60/248 (24.2%) 0/4 (0.0%) 128/653 (16.4%) ,.001 ,.001
ACE-ARB 358/724 (49.5%) 232/332 (69.9%) 590/1056 (55.9%) ,.001 ,.001
CV event 38/693 (5.5%) 77/325 (23.7%) 1/5 (20.0%) 116/1023 (11.3%) ,.001 ,.001
MS: metabolic syndrome, MAU: microalbuminuria, ACE-I/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker, CVevent: cardiovascular event.
p*:p values between all three groups; p1: p value between users vs. non statin users.
doi:10.1371/journal.pone.0031639.t001
Table 2. Baseline characteristics (continuous variables).
Patient Characteristic Statistic No statin Statin
Statin use
unknown Total P* P1
Age (years) Mean6SD 56.867.6 59.167.1 58.266.0 57.567.5 ,.001 ,.001
Median 57.2 60.0 58.6 58.5
N 724 332 19 1075
BMI (kg/m2) Mean6SD 29.365.4 30.665.5 30.564.4 29.765.4 0.001 ,.001
Median 28.5 29.7 31.7 28.8
N 689 326 5 1020
SBP (mmHg) Mean6SD 143.5615.4 142.6616.3 148.5610.6 143.3615.7 0.527 0.394
Median 142.5 140.0 152.0 142.0
N 704 331 5 1040
DBP (mmHg) Mean6SD 84.469.7 82.969.9 86.765.8 84.069.8 0.054 0.020
Median 84.5 82.0 86.5 83.5
N 704 331 5 1040
Glucose (mmol/l) Mean6SD 5.662.9 6.362.1 6.861.4 5.962.7 0.001 ,.001
Median 5.2 5.7 6.9 5.3
N 644 311 4 959
Uric acid (mmol/l) Mean6SD 339689 357683 291683 345689 0.008 0.004
Median 333 357 286 339
N 629 306 4 939
Triglycerides (mmol/l) Mean6SD 1.661.1 1.961.1 2.061.7 1.761.1 0.011 0.003
Median 1.3 1.6 1.4 1.4
N 638 316 4 958
LDL-Cholesterol (mmol/l) Mean6SD 3.260.8 2.761.0 2.960.8 3.060.9 ,.001 ,.001
Median 3.2 2.6 3.2 3.0
N 628 312 4 944
HDL-Cholesterol (mmol/l) Mean6SD 1.560.5 1.460.4 1.360.4 1.560.5 0.004 0.001
Median 1.4 1.3 1.4 1.4
N 637 315 4 956
CRP (mg/dl) Mean6SD 0.560.8 0.460.5 0.460.4 0.560.7 0.148 0.055
Median 0.3 0.2 0.4 0.3
N 608 291 4 903
BMI: body mass index, SBP: systolic blood pressure, DBP diastolic blood pressure, CRP: C-reactive protein. p*:p values between all three groups; p1: p value between
users vs. non statin users.
doi:10.1371/journal.pone.0031639.t002
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(p,0.001), serum uric acid (p = 0.004), and triglycerides
(p = 0.003), had lower levels of LDL (p,0.001) and HDL
cholesterol (p = 0.001) compared to patients not taking statins
(tables 1 and 2). The univariable odds ratio of MAU in patients
using vs. not using a statin was 2.01 (95% CI: 1.34–3.01,
p = 0.0009, table 3A).
After multivariable analysis including the propensity score for
statin use, the odds of MAU was still significantly higher in patients
taking a statin (OR: 1.82, 95% CI: 1.14–2.91, p = 0.01, table 3B).
When all other variables were forced into the model, use of statin
still was independently associated with a higher odds of MAU
(OR: 1.90, 95% CI: 1.15–3.11, p= 0.01, table 3C). Next to statin
use, only diabetes (OR: 1.92, 95% CI: 1.00–3.66, p= 0.05) and
smoking (OR: 1.49, 95% CI: 0.99–2.26, p = 0.06) were indepen-
dently associated with MAU after adjusting for the likelihood of
receiving a statin, suggesting that prescription of a statin overrides
the association between cardiovascular risk factors, MAU and
creates collinearity by acting as a surrogate.
Discussion
Our data create concern on the use of MAU as a predictor or
marker of cardiovascular or renal disease in cohorts with patients
using statins. Statin use apparently could blur the interpretation of
MAU by two potential mechanisms: 1u higher prevalence of MAU
in patients using a statin, even after correction for bias by
indication and 2u masking of cardiovascular risk factors in
multivariable analyses, as statin use behaves as a surrogate for
these markers. In epidemiological studies evaluating the associa-
tion between cardiovascular risk factors and MAU, statin use can
induce incorrect labeling of patients as having a cardiovascular or
renal risk factor, and interpretation of other risk factors for
cardiovascular or renal disease can be confounded by the way the
use of statins is handled in the analysis. In this cross-sectional
analysis, we observed a two-fold higher prevalence of MAU in
subjects who use vs. those who do not use a statin. However, part
of this association (figure S1) can be attributed to bias by
indication, as patients are often prescribed statins because they
have cardiovascular risk factors which are by themselves associated
with enhanced risk for MAU. Indeed, we observed a higher
prevalence of cardiovascular risk factors in patients taking vs. not
taking a statin in our study. We tried to exclude this bias by
indication by the use of a propensity score analysis. Adjusting for
the propensity score allows to analyze the difference in occurrence
of MAU between patients with a comparable propensity to receive
a statin, while one group does whereas the other does not receive
the drug. The technique of propensity score is well established to
address confounding and bias by indication in observational
studies [23,24]. However, this increased odds ratio remained
present even after correcting for the fact that statins are usually
prescribed in patients with cardiovascular risk factors which by
themselves are associated with MAU, using the robust technique
of propensity score. This observation can either be due to residual
or unmeasured confounding or there can really be an induction of
MAU by statin use (figure S1). Our data stress that statin use
confounds the impact of the individual risk factors on MAU, as
statin use behaves as a surrogate for presence of cardiovascular risk
factors. As a consequence, in studies where MAU is either used as
a marker or as a surrogate endpoint, the association between
outcomes and certain cardiovascular risk factors can be blurred,
and this in an unpredictable and variable fashion, depending upon
the prevalence of statin use in the cohort. On the other hand, if
statins really induce MAU, theoretically it can be both of
glomerular or of tubular origin (figure S1). We did not find any
publication, either human, animal or in vitro, indicating that statin
associated proteinuria is of glomerular origin, but at least three in
vitro or animal studies demonstrated that statins do inhibit tubular
reabsorption of filtered albumin and in this way could generate
MAU in a dose-dependent manner and in absence of cytotoxicity
[11,12,25]. There is also growing evidence that also in other
conditions MAU can be the consequence of tubular dysfunction,
even in presence of an entirely intact glomerulus [26,27]. One
epidemiological study in humans also coined statin induced
proteinuria as being tubular in origin, and even demonstrated a
dose-effect relation with rosuvastatin [28]. This would explain why
statins fail to consistently result in reduction of MAU in subjects
with low grade MAU, or why higher vs. lower doses of statin fail to
further reduce MAU [29,30], as the beneficial effect of statins on
the glomerular MAU is counterbalanced by the induction of
tubular MAU. It is very unlikely that statin induced MAU is
associated with an increased cardiovascular risk, but its impact on
the functional capacity and the morphological integrity of the
kidneys is unknown. Even when the tubular albuminuria induced
by statins is harmless [31], it interferes with the implication of
MAU as predictor or marker of cardiovascular and renal risk by
incorrectly labeling a subject as having a risk factor. Of note, this
would imply that the prognostic impact of glomerular MAU (so
not induced by statin use) in populations with a high prevalence of
statin use, would be underestimated. The hypothesis that statin
induced MAU is tubular in origin would also fit with the favorable
Table 3. Association between statin use and
microalbuminuria (MAU).
Odds Ratio
Logistic regression
model for presence
of MAU Parameter Estimate
95%
Confidence
Interval P-value
A. Univariable
association
Statin use 2.01 (1.34;3.01) ,0.001
B. Association adjusted
for propensity score
Statin use 1.82 (1.14; 2.91) 0.01
Pscore$ . 0.6
C. Association fully
adjusted
Statin use 1.90 (1.15; 3.11) 0.01
Pscore 7.92 (0.18; 357.3) 0.28
Age 1.02 (0.91; 1.14) 0.74
Diabetes 1.92 (1.004; 3.66) 0.05
Smoker 1.49 (0.99; 2.26) 0.06
ACE-I/ARB 1.47 (0.92; 2.34) 0.11
CV event 1.32 (0.59; 2.95) 0.50
BMI 1.03 (0.86; 1.24) 0.74
Mean BP 0.96 (0.89; 1.04) 0.35
Fasting glucose 0.97 (0.91; 1.04) 0.44
Uric acid 0.89 (0.50; 1.50) 0.61
Triglycerides 0.99 (0.98; 1.01) 0.44
Cholesterol 1.00 (0.98; 1.02) 0.77
CRP 1.49 (0.01; 359.73) 0.89
$ Pscore = propensity score; The propensity score was fit using a restricted cubic
spline.
ACE-I/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor
blocker, CV event: cardiovascular event, BMI: body mass index, BP: Blood
pressure, CRP: C-reactive protein.
doi:10.1371/journal.pone.0031639.t003
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effect of statins on cardiovascular disease and on progression of
renal disease, as these effects are related to the reduction of
glomerular MAU associated with the improvement of endothelial
dysfunction [32,33].
Limitations
This cross-sectional study could not prove a causal connection
between statin use and de novo MAU. Using the technique of
propensity score we achieved ‘‘pseudo-randomization’’, which in
fact obviates the drawbacks imposed by the method of the study,
but which is not free from unmeasured biases [24]. Unfortunately,
although dose dependency and a higher frequency of more potent
inhibitors of HMG coA reductase could add further strength to the
association with MAU, the prescribed daily dose and type of statin
were as per protocol not registered in our study. Another
limitation of our study is that MAU was measured in a single
morning urine, whereas guidelines recommend to have at least two
positive MAU in three consecutive first morning urine samples
before labeling a person as having MAU [34]. However, in view of
the mechanism of inhibition of tubular endocytosis, it is unlikely
that statin associated MAU would disappear by repeated testing,
unless the statin would be stopped temporarily to confirm the
diagnosis. Second, intermittent MAU should not be considered as
a predictor or marker of cardiovascular or renal risk, as it is not
linked to endothelial dysfunction [35]. In line with this, we
demonstrated in another cohort, that patients with intermittent
MAU have far less cardiovascular risk factors as compared to
patients with persisting MAU [36]. Our study shows that, in
addition to the problems caused by single vs. multiple sampling,
the use of a statin can also lead to an in incorrect labeling of
subject as having MAU.
The strength of this study is that it reflects routine clinical
practice in hypertensive patients. To the best of our knowledge,
this is the first study pointing to an independent association
between statin use and MAU, even after correction for bias by
indication by the use of a propensity score, underlining the
potential consequences of confounding induced by statin use on
the interpretation of MAU as a predictor or marker of
cardiovascular or renal disease in epidemiological trials.
According to our data, statins are independently associated with
an increased prevalence of MAU, even after correction for bias by
indication. As this MAU is most likely of tubular origin, it is
uncertain and rather unlikely whether it has the same prognostic
impact for renal and cardiovascular disease as endothelial
dysfunction induced glomerular MAU. As such, it can lead to
incorrect labeling of subjects as having a cardiovascular risk factor.
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